SAGE Therapeutics Inc (SAGE) Expected to Post Earnings of -$2.04 Per Share
Analysts predict that SAGE Therapeutics Inc (NASDAQ:SAGE) will announce earnings per share (EPS) of ($2.04) for the current quarter, Zacks reports. Zero analysts have made estimates for SAGE Therapeutics’ earnings. The lowest EPS estimate is ($2.35) and the highest is ($1.79). SAGE Therapeutics reported earnings of ($1.50) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 36%. The firm is scheduled to announce its next quarterly earnings results on Thursday, February 22nd.
According to Zacks, analysts expect that SAGE Therapeutics will report full-year earnings of ($7.42) per share for the current fiscal year, with EPS estimates ranging from ($7.73) to ($7.16). For the next year, analysts forecast that the company will post earnings of ($7.69) per share, with EPS estimates ranging from ($9.08) to ($6.43). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow SAGE Therapeutics.
SAGE Therapeutics (NASDAQ:SAGE) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.98) by $0.01. The business’s revenue for the quarter was up .0% compared to the same quarter last year.
Shares of SAGE Therapeutics (NASDAQ:SAGE) traded up $2.75 on Friday, reaching $169.46. 369,084 shares of the company traded hands, compared to its average volume of 602,377. SAGE Therapeutics has a fifty-two week low of $44.55 and a fifty-two week high of $180.83. The firm has a market capitalization of $6,960.00, a PE ratio of -24.67 and a beta of 3.05.
In other news, insider Stephen Kanes sold 44,000 shares of the stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $177.18, for a total value of $7,795,920.00. Following the transaction, the insider now directly owns 46,348 shares of the company’s stock, valued at $8,211,938.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Albert Robichaud sold 60,000 shares of the stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the completion of the transaction, the insider now directly owns 152,759 shares in the company, valued at $24,354,367.37. The disclosure for this sale can be found here. Insiders have sold 314,247 shares of company stock worth $50,465,110 over the last ninety days. Insiders own 6.10% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its position in shares of SAGE Therapeutics by 5.9% in the second quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock valued at $241,431,000 after purchasing an additional 168,424 shares during the period. Vanguard Group Inc. raised its position in shares of SAGE Therapeutics by 2.2% in the second quarter. Vanguard Group Inc. now owns 2,749,954 shares of the biopharmaceutical company’s stock valued at $219,006,000 after purchasing an additional 58,679 shares during the period. Bank of New York Mellon Corp raised its position in shares of SAGE Therapeutics by 36.5% in the third quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock valued at $168,834,000 after purchasing an additional 724,494 shares during the period. State Street Corp raised its position in shares of SAGE Therapeutics by 7.7% in the second quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock valued at $96,558,000 after purchasing an additional 87,097 shares during the period. Finally, Oak Ridge Investments LLC raised its position in shares of SAGE Therapeutics by 0.9% in the third quarter. Oak Ridge Investments LLC now owns 736,709 shares of the biopharmaceutical company’s stock valued at $45,897,000 after purchasing an additional 6,835 shares during the period. 95.33% of the stock is currently owned by institutional investors.
About SAGE Therapeutics
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.